Natalizumab in the treatment of pediatric multiple sclerosis

Abstract

Pediatric cerebrospinal multiple sclerosis (MS) constitutes about 2-5% of all MS cases. The International Pediatric MS Study Group (IPMSSG) applies diagnostic criteria for adults to MS in childhood and adolescence.

Keywords

• Natalizumab
• treatment
• pediastric
• multiple
• sclerosis